LSA
CRVS icon

Leonteq Securities AG’s Corvus Pharmaceuticals CRVS Stock Holding History

Leonteq Securities AG’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,000
Closed -$64.4K – 1283
2025
Q1 		$64.4K Buy
+20,000
New +$94.2K ﹤0.01% 798
2022
Q4 		– Sell
-10,000
Closed -$8.19K – 1307
2022
Q3 		$8.19K Buy
10,000
+2,000
+25% +$1.91K ﹤0.01% 1078
2022
Q2 		$7.92K Sell
8,000
-7,000
-47% -$8.59K ﹤0.01% 1116
2022
Q1 		$24.6K Buy
15,000
+14,000
+1,400% +$25.6K ﹤0.01% 977
2021
Q4 		$2.41K Buy
+1,000
New +$3.88K ﹤0.01% 1212

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return